Sellas Life Sciences (SLS) stock extended its three-week winning streak after MassMutual disclosed a 24-share position as of June 30. MassMutual Private Wealth & Trust reported the stake, valued at $354.24, on July 2 ahead of Sellas' Phase 3 Regal trial readout for acute myeloid leukemia (AML). The trial has reached 78 of the 80 events required to trigger final analysis. SLS stock rose 21% last week but declined 1% late Sunday. The trial tests galinpepimut-S (GPS) in AML patients, with Sellas targeting median overall survival of 12.6 months versus 8 months under standard treatment. CEO Angelos Stergiou previously described the slower-than-expected event accumulation as an encouraging sign.
MassMutual and First Financial Bank Disclose SLS Positions
MassMutual Private Wealth & Trust, FSB disclosed ownership of 24 SLS shares as of June 30, with the stake valued at $354.24 and reported on July 2. MassMutual's 13F filing disclosed 2,495 stock positions with total holdings of $3.84 billion, including Apple, Nvidia, and Visa as its largest holdings. First Financial Bank held 10,000 SLS shares, valued at $147,600, as of June 30, reported last week.
Sellas Phase 3 Regal Trial Reaches 78 of 80 Events
The Phase 3 Regal trial of galinpepimut-S (GPS) in AML has reached 78 of the 80 events required to trigger final analysis. Sellas previously stated the trial would be considered successful if GPS extends median overall survival to 12.6 months, compared with 8 months under standard treatment. CEO Angelos Stergiou called the slower-than-expected event accumulation an encouraging sign.
CEO Post and Severance Amendments Fuel Buyout Speculation
Stergiou's Fourth of July LinkedIn post referenced "clinical investigators, research sites, collaborators, strategic partners, and shareholders," stating "Meaningful innovation is never achieved alone" and expressing optimism about the future. Sellas updated executive severance and change-of-control arrangements, with Stergiou's amended agreement shifting certain change-of-control severance payments to a lump sum. CFO John Burns and Chief Development Officer Dragan Cicic would receive 15 months of base salary, target bonus payments, COBRA reimbursement, and full equity acceleration under qualifying change-of-control terminations.
Sellas Market Cap and Cash Position
Sellas' market cap grew from $73 million at the start of 2024 to more than $1.5 billion by mid-2026. The company ended the first quarter with $107.1 million in cash and raised another $28.7 million through warrant exercises in April and May. Shareholders approved a 20 million-share increase to Sellas' 2023 Equity Incentive Plan. Stergiou was awarded 1.065 million restricted stock units vesting over four years, increasing his ownership to 1.76 million shares. SLS stock has surged 607% over the past year.
FAQ
What stake did MassMutual disclose in SLS stock?
MassMutual Private Wealth & Trust disclosed ownership of 24 SLS shares, valued at $354.24 as of June 30 and reported on July 2.
How close is Sellas' Phase 3 Regal trial to final analysis?
The trial has reached 78 of the 80 events required to trigger final analysis. Sellas targets median overall survival of 12.6 months versus 8 months under standard treatment.
What did Sellas' CEO say in his Fourth of July post?
CEO Angelos Stergiou referenced "strategic partners" and stated "Meaningful innovation is never achieved alone," expressing optimism about the future. The post fueled retail buyout speculation.
